Pneumonia is a leading cause of death and hospitalization, costing health care systems billions of dollars and an estimated 600,000 adult deaths worldwide each year. Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and the term describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections. Although all age groups may be affected, the highest rate of pneumococcal disease occurs in young children and older adults. In addition, persons suffering from a wide range of chronic conditions (eg, diabetes, cardiovascular disease) and immune deficiencies are at increased risk.
Pneumonia Symptoms & Risk Factors
Pneumonia is an acute respiratory infection where the alveolar sacs of the lungs become inflamed and fill with fluid or pus.
WHO's first release of surveillance data on antibiotic resistance reveals high levels of resistance to a number of serious bacterial infections in both high- and low-income countries.
A group of over 120 researchers from various institutions across Europe has performed the first genome-wide association study to reveal host genetic factors that may contribute to respiratory failure in cases of coronavirus disease 209 (COVID-19).
A study of teens diagnosed with the vaping-linked respiratory disease EVALI revealed that most also had gastrointestinal symptoms and a history of psychosocial factors, including substance abuse, UT Southwestern researchers found in one of the first clinical reviews of its kind.
Now, in a significant scientific study, a team of researchers at the University of North Carolina Health Care (UNC) have mapped how SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19), infects the nasal cavity, the airways, and down to the lungs.
The latest generation of tetracyclines - a class of powerful, first-line antibiotics - was designed to thwart the two most common ways bacteria resist such drugs.
The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.
Patients undergoing surgery after contracting coronavirus are at greatly increased risk of postoperative death, a new global study published in The Lancet reveals.
Simon Fraser University researchers and Providence Health Care are collaborating on a new artificial intelligence tool that will help diagnose COVID-19 quicker.
In a major scientific study published in the journal Cell, scientists at the UNC School of Medicine and the UNC Gillings School of Global Public Health have characterized the specific ways in which SARS-CoV-2 – the coronavirus that causes COVID-19 – infects the nasal cavity to a great degree – replicating specific cell types – and infects and replicates progressively less well in cells lower down the respiratory tract, including the lungs.
A recent paper published online on the preprint server medRxiv in May 2020 reports autopsy results on COVID-19 patients. The paper concludes that there were no specific hallmark lesions of COVID-19 in any of the many organs found to be injured by the infection in patients who died of the disease.
A new paper published in the journal JAMA Neurology in May 2020 discusses the presentation and complications of COVID-19 with respect to the nervous system.
A new research paper published in the journal JAMA Network Open in May 2020 reports a high incidence of deep vein clots in patients with severe COVID-19 at a single French medical center. This could indicate the need for systematic anticoagulant therapy in these patients as a preventive measure.
Even as the COVID-19 pandemic was sweeping across the world, new symptoms and clinical presentations appeared, often confusing the picture. A case report from Italy, published in the journal JAMA Neurology in May 2020, shows that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be a neurotropic virus, and may cause infection to present primarily with anosmia.
As if the COVID-19 pandemic isn't scary enough, the flu season is not far away. How severe will the flu season be as it converges with the COVID-19 outbreak? What can we do to prepare?
With more than 5.8 million people infected with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the search is on for an effective SARS-CoV-2 vaccine or drug to treat COVID-19 disease.
Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.
A mouse model of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reproduces features observed in human patients, researchers report May 26 in the journal Cell Host & Microbe.
Students at Cranfield University have designed computer models that can identify COVID-19 in X-rays.
We recently received the death certificate for my mother, who died May 4 in an assisted living facility near New York City. "Acute Respiratory Distress Syndrome" was the primary cause. And the secondary — no surprise — was "suspected COVID-19."
The hypothesis that blood clotting disorders may explain some of the worst symptoms of COVID-19, including respiratory failure and pulmonary fibrosis, was suggested in mid-April by researchers in Brazil affiliated with the University of São Paulo's Medical School (FM-USP) via an article accepted for publication by the Journal of Thrombosis.